The Epidermal Growth Factor Receptor: A Link Between Inflammation and Liver Cancer
- 1 July 2009
- journal article
- review article
- Published by Frontiers Media SA in Experimental Biology and Medicine
- Vol. 234 (7), 713-725
- https://doi.org/10.3181/0901-mr-12
Abstract
Epidemiological studies have established that many tumours occur in association with persistent inflammation. One clear example of inflammation-related cancer is hepatocellular carcinoma (HCC). HCC slowly unfolds on a background of chronic inflammation triggered by exposure to infectious agents (hepatotropic viruses), toxic compounds (ethanol), or metabolic impairment. The molecular links that connect inflammation and cancer are not completely known, but evidence gathered over the past few years is beginning to define the precise mechanisms. A central role for cytokines such as interleukin-6 (IL-6) and IL-1 (α and β) in liver cancer has been established in experimental models. Besides these inflammatory mediators, mounting evidence points to the dysregulation of specific growth and survival-related pathways in HCC development. Among them is the pathway governed by the epidermal growth factor receptor (EGFR), which can be bound and activated by a broad family of ligands. Of special relevance is the fact that the EGFR engages in extensive crosstalk with other signaling pathways, serving as a “signaling hub” for an increasing list of growth factors, cytokines, and inflammatory mediators. In this review, we summarize the most recent evidences supporting a role for the EGFR system in inflammation-related cell signaling, with special emphasis in liver inflammation and HCC. The molecular dissection of the pathways connecting the inflammatory reaction and neoplasia will facilitate the development of novel and more effective antitumor strategies.Keywords
This publication has 113 references indexed in Scilit:
- Hepatocyte Necrosis Induced by Oxidative Stress and IL-1α Release Mediate Carcinogen-Induced Compensatory Proliferation and Liver TumorigenesisCancer Cell, 2008
- Molecular targeted therapies in hepatocellular carcinomaHepatology, 2008
- The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosisHepatology, 2008
- The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancerTrends in Molecular Medicine, 2008
- NF-κB and cancer—identifying targets and mechanismsCurrent Opinion in Genetics & Development, 2008
- Cyclooxygenase-2 transactivates the epidermal growth factor receptor through specific E-prostanoid receptors and Tumor Necrosis Factor-α converting enzymeCellular Signalling, 2007
- Mitogenic signaling pathways induced by G protein‐coupled receptorsJournal of Cellular Physiology, 2007
- Liver regenerationJournal of Cellular Physiology, 2007
- EGF–ERBB signalling: towards the systems levelNature Reviews Molecular Cell Biology, 2006
- Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosisHepatology, 2005